NASDAQ:APLS Apellis Pharmaceuticals Q1 2026 Earnings Report $41.03 0.00 (0.00%) As of 05/14/2026 ProfileEarnings HistoryForecast Apellis Pharmaceuticals EPS ResultsActual EPS$0.15Consensus EPS -$0.29Beat/MissBeat by +$0.44One Year Ago EPSN/AApellis Pharmaceuticals Revenue ResultsActual Revenue$268.30 millionExpected Revenue$208.91 millionBeat/MissBeat by +$59.38 millionYoY Revenue GrowthN/AApellis Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time4:00PM ETUpcoming EarningsApellis Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Apellis Pharmaceuticals Earnings HeadlinesMid Cap Stocks To Follow Today - May 19thMay 21 at 4:07 AM | americanbankingnews.comPromising Mid Cap Stocks To Keep An Eye On - May 15thMay 17, 2026 | americanbankingnews.comSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June 4th. The company recently issued a 5-for-1 stock split, dropping shares from $526 to roughly $105 - a deliberate move to open access to everyday investors. SpaceX controls two-thirds of all satellites in orbit, accounts for 85% of global rocket launches, and has collected $13 billion from NASA over the past decade. Analyst Matt McCall has spent months researching how investors can get a stake before the IPO through a regular brokerage account, for less than $100.May 22 at 1:00 AM | NXT Wave Research (Ad)Top Pharmaceutical Stocks To Add to Your Watchlist - May 14thMay 16, 2026 | americanbankingnews.comBest Medical Stocks To Keep An Eye On - May 14thMay 16, 2026 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Upgraded at Wall Street ZenMay 16, 2026 | americanbankingnews.comSee More Apellis Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Apellis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apellis Pharmaceuticals and other key companies, straight to your email. Email Address About Apellis PharmaceuticalsApellis Pharmaceuticals (NASDAQ:APLS), traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life. The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders. In addition to its ophthalmology programs, Apellis is advancing clinical candidates in hematology, including indications such as paroxysmal nocturnal hemoglobinuria (PNH), and in rare kidney diseases like C3 glomerulopathy. Its diversified pipeline reflects a strategy to address high-unmet-need populations across multiple therapeutic areas. Founded in 2003 and headquartered in Waltham, Massachusetts, Apellis operates with a global footprint, conducting clinical trials and engaging regulatory authorities in key markets including the United States, Europe and Asia. The company collaborates with research institutions and industry partners to enhance its discovery engine and advance its development candidates from preclinical studies through late-stage trials. Apellis is led by President and Chief Executive Officer Cedric Francois, who brings extensive experience in biotechnology and drug development. Under his leadership, the company continues to expand its scientific capabilities and pursue strategic initiatives aimed at delivering transformative therapies to patients worldwide.View Apellis Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See MoreLowe's Finds Support at $215 After Q1 Earnings Sell-Off Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
